With the patent for Novo Nordisks semaglutide, a key ingredient in popular obesity drugs, set to expire in 2026, several Indian drugmakers have applied for the governments production-linked incentive (PLI) scheme
But one of the first questions we always get is: "How much weight can I actually lose on Semaglutide?" Lets break it down
Regulation of skin lightening agents in the United States and implications for public health
3 Key Considerations for Plan Sponsors As you evaluate your plan benefit philosophy, including whether or not to cover the use of these drugs for weight loss, and prioritize what is most important to you, consider three key areas: Coverage, Cost and Care
The obesity treatment landscape just shifted dramatically
it readies body tissues for pregnancy